Pharmacokinetics of posaconazolewithin epithelial cells and fungi: Insights into potential mechanisms of action during treatment and prophylaxis

Journal of Infectious Diseases

Volumn 208, Issue 10, 2013, Pages 1717-1728

  Campoli, Paolo ^a   Perlin, David S ^c   Kristof, Arnold S ^b   White, Theodore C ^d   Filler, Scott G ^e   Sheppard, Donald C ^a  

^a 3775 University   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Endoplasmic reticulum; Epithelial cells; Hydrophobin roda; Localization; Pharmacokinetics; Posaconazole; Postantifungal effect

Indexed keywords

BORON DIPYRROMETHENE; FLUORESCENT DYE; HYDROPHOBIN; POSACONAZOLE; RED FLUORESCENT PROTEIN; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT; PROTEIN BINDING; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CELL MEMBRANE; CELLULAR DISTRIBUTION; COCULTURE; COMPETITIVE INHIBITION; CONFOCAL MICROSCOPY; CONIDIUM; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TRANSPORT; ENDOPLASMIC RETICULUM; EPITHELIUM CELL; FLOW CYTOMETRY; FUNGAL CELL; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; TRANSPORT KINETICS; ANTIBIOTIC PROPHYLAXIS; CELL LINE; DRUG EFFECTS; FUNGUS; FUNGUS SPORE; METABOLISM; MYCOSES; TRANSPORT AT THE CELLULAR LEVEL; ASPERGILLUS; DRUG EFFECT; HYDROPHOBIN RODA; LOCALIZATION; MYCOSIS; PHARMACOKINETICS; POSTANTIFUNGAL EFFECT; PROTEIN BINDING;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE; EPITHELIAL CELLS; FUNGI; HUMANS; MYCOSES; PROTEIN BINDING; SPORES, FUNGAL; TRIAZOLES;

ASPERGILLUS; ENDOPLASMIC RETICULUM; EPITHELIAL CELLS; HYDROPHOBIN RODA; LOCALIZATION; PHARMACOKINETICS; POSACONAZOLE; POSTANTIFUNGAL EFFECT;

EID: 84888609374     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit358     Document Type: Article

References (30)

1. Balloy V, Chignard M. The innate immune response to Aspergillus fumigatus. Microbes Infect 2009; 11:919-27.
2. Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2010; 54:4143-9.
3. Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46:212-29.
4. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev 2010; 24:51-61.
5. Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: An update. Mycopathologia 2009; 168:313-27.
6. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
7. Ullmann AJ, Krammes E, Sommer S, et al. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats. J Antimicrob Chemother 2007; 60:1080-4.
8. Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/ itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012; 97:459-63.
9. Farowski F, Cornely OA, Vehreschild JJ, et al. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother 2010; 54:2928-31.
10. Conte JE Jr, DeVoe C, Little E, Golden JA. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54:3609-13.
11. Conte JE Jr, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother 2009; 53:703-7.
12. Campoli P, Al Abdallah Q, Robitaille R, et al. Concentration of antifungal agents within host cell membranes: A new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother 2011; 55: 5732-9.
13. Lignell A, Lowdin E, Cars O, Chryssanthou E, Sjolin J. Posaconazole in human serum: A greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob Agents Chemother 2011; 55:3099-104.
14. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. Posaconazole exposureresponse relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56:2806-13.
15. Pratt A, Garcia-Effron G, Zhao Y, et al. Evaluation of fungal-specific fluorescent labeled echinocandin probes as diagnostic adjuncts. Med Mycol 2012; 51:103-7.
16. Thau N, Monod M, Crestani B, et al. Rodletless mutants of Aspergillus fumigatus. Infect Immun 1994; 62:4380-8.
17. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: Approved standard-second edition. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
18. Twumasi-Boateng K, Yu Y, Chen D, Gravelat FN, NiermanWC, Sheppard DC. Transcriptional profiling identifies a role for BrlA in the response to nitrogen depletion and for StuA in the regulation of secondary metabolite clusters in Aspergillus fumigatus. Eukaryot Cell 2009; 8:104-15.
19. Fielhaber JA, Tan J, Joung KB, et al. Regulation of karyopherin alpha1 and nuclear import by mammalian target of rapamycin. J Biol Chem 2012; 287:14325-35.
20. Lopes Bezerra LM, Filler SG. Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood 2004; 103:2143-9.
21. Sheppard DC. Molecular mechanism of Aspergillus fumigatus adherence to host constituents. Curr Opin Microbiol 2011; 14:375-9.
22. Warrilow AG, Melo N, Martel CM, et al. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. Antimicrob Agents Chemother 2010; 54:4225-34.
23. Fraczek MG, Bromley M, Bowyer P. An improved model of the Aspergillus fumigatus CYP51A protein. Antimicrob Agents Chemother 2011; 55:2483-6.
24. Hand WL, Hand DL. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents 2001; 18:419-25.
25. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
26. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009-15.
27. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004; 48:568-74.
28. Munayyer HK, Mann PA, Chau AS, et al. Posaconazole is a potent inhibitor of sterol 14 alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother 2004; 48:3690-6.
29. Chen CK, Leung SS, Guilbert C, Jacobson MP, McKerrow JH, Podust LM. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 2010; 4:e651.
30. Mansfield BE, Oltean HN, Oliver BG, et al. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog 2010; 6:e1001126.